Industry Insight
Discovery Technology
Analytical Laboratory Technology
Delivery Systems
Ingredients, Formulation and Finishing
View our other publications with free access to extensive archives


 16th September 2009 Merck

Merck Serono Growth Hormone Injection Device easypod® Approved in Japan Geneva, Switzerland, September 16, 2009 – Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod® in Japan. Easypod® was developed for exclusive use with cartridges of Saizen® (somatropin), Merck Serono’s human recombinant growth hormone for the treatment of growth hormone deficiency. Easypod® is an innovative electronic auto injection device designed to improve ease of usage, reliability and convenience for patients who need daily subcutaneous injections of Saizen®. It allows patients to self-inject in just three simple key steps. Additionally, a built-in dose memory automatically records the number of doses administered, allowing physicians and caregivers to accurately monitor patient adherence to therapy. “Easypod is both an easy to use and intelligent device enabling physicians to track patients’ adherence to Saizen therapy, which is an essential component for optimal treatment outcomes,” said Franck Latrille, Executive Vice President, Head of Commercial International at Merck Serono. “We are pleased to offer this innovative and successful device today to patients in Japan.” Easypod® is registered in 39 other countries worldwide including European countries and the United States. In Japan, easypod® will be launched in the course of 2009.


Advair,Flovent,VentolinSymbicort,Serevent,FlonaseAstelin Rhinocort
IPT © 2021 Innovations in Pharmaceutical Technology | Terms and Conditions | | UK Contacts |
Providing a platform of communication on new ideas, developments and innovations | UK Tel No. +44 20 77243456 | Back to top of page |